## Youwen Zhou

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1260798/publications.pdf

Version: 2024-02-01

		361413	395702
38	1,195	20	33
papers	citations	h-index	g-index
38	38	38	2172
30	30	30	21/2
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology, 2022, 8, 618.	7.1	46
2	Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response. Frontiers in Immunology, 2021, 12, 613031.	4.8	7
3	Representation of sex, race, and ethnicity in pivotal clinical trials for dermatological drugs. International Journal of Women's Dermatology, 2021, 7, 428-434.	2.0	22
4	Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. Journal of Autoimmunity, 2021, 123, 102707.	6.5	27
5	Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. Journal of Cutaneous Medicine and Surgery, 2019, 23, 537-544.	1.2	18
6	Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas. Molecules, 2019, 24, 3459.	3.8	6
7	Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases. Journal of Investigative Dermatology, 2019, 139, 789-795.	0.7	35
8	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunology Research, 2019, 7, 1064-1078.	3.4	104
9	A Vision for an Academic Career Mentorship Program for Canadian Dermatology Residents. Journal of Cutaneous Medicine and Surgery, 2019, 23, 123-124.	1.2	2
10	Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma. Journal of Cutaneous Medicine and Surgery, 2019, 23, 319-327.	1.2	5
11	IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model. Leukemia and Lymphoma, 2019, 60, 1244-1252.	1.3	14
12	Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease. Human Pathology, 2018, 77, 152-158.	2.0	19
13	Drug Eruption to Rosuvastatin With Recurrence on Simvastatin: A Case Report. Journal of Cutaneous Medicine and Surgery, 2018, 22, 359-361.	1.2	7
14	Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis. Scientific Reports, 2018, 8, 16867.	3.3	5
15	Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Scientific Reports, 2017, 7, 44015.	3.3	47
16	Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. Mediators of Inflammation, 2017, 2017, 1-13.	3.0	32
17	Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma. Oncology Letters, 2016, 12, 3089-3100.	1.8	7
18	Novel Quinazoline Derivatives Bearing Various 4â€Aniline Moieties as Potent <scp>EGFR</scp> Inhibitors with Enhanced Activity Against <scp>NSCLC</scp> Cell Lines. Chemical Biology and Drug Design, 2016, 87, 635-643.	3.2	10

#	Article	IF	Citations
19	The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). Journal of the American Academy of Dermatology, 2016, 75, 1126-1133.	1.2	59
20	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a <i>N</i> ,9-Diphenyl-9 <i>H</i> -purin-2-amine Scaffold. ACS Medicinal Chemistry Letters, 2016, 7, 1050-1055.	2.8	24
21	CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. Scientific Reports, 2016, 6, 29719.	3.3	119
22	Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2016, 59, 6580-6594.	6.4	84
23	Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. European Journal of Medicinal Chemistry, 2016, 110, 195-203.	5.5	24
24	Hyperhidrosis Prevalence and Demographical Characteristics in Dermatology Outpatients in Shanghai and Vancouver. PLoS ONE, 2016, 11, e0153719.	2.5	40
25	Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. Blood, 2015, 125, 1435-1443.	1.4	61
26	Stage-specific prognostic biomarkers in melanoma. Oncotarget, 2015, 6, 4180-4189.	1.8	26
27	Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients. Oncotarget, 2015, 6, 14374-14384.	1.8	4
28	Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget, 2015, 6, 28502-28512.	1.8	19
29	Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget, 2015, 6, 23026-23035.	1.8	12
30	IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle, 2014, 13, 1306-1312.	2.6	27
31	Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. Oncolmmunology, 2014, 3, e970025.	4.6	38
32	SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood, 2014, 123, 3452-3461.	1.4	31
33	Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients. Clinical Cancer Research, 2014, 20, 3799-3808.	7.0	40
34	Assessing adherence with phototherapy protocols. Journal of the American Academy of Dermatology, 2014, 71, 1259-1261.	1.2	10
35	Depletion of M2-Like Tumor-Associated Macrophages Delays Cutaneous T-Cell Lymphoma Development In Vivo. Journal of Investigative Dermatology, 2014, 134, 2814-2822.	0.7	102
36	The Role Of BIN1 Tumor Suppressor Isoforms In Regulation Of Proliferation, Apoptosis and Tumor Formation Of Human Cutanous T-Cell Lymphoma Cells In Vitro and In Vivo. Blood, 2013, 122, 2517-2517.	1.4	0

## Youwen Zhou

#	Article	IF	CITATIONS
37	Mycophenolate Mofetil (CellCept�) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. Journal of Cutaneous Medicine and Surgery, 2003, 7, 193-197.	1.2	24
38	Mycophenolate Mofetil (CellCept®) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. Journal of Cutaneous Medicine and Surgery, 2003, 7, 193-197.	1.2	38